These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 33579873)

  • 41. Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed.
    Titova N; Martinez-Martin P; Katunina E; Chaudhuri KR
    J Neural Transm (Vienna); 2017 Dec; 124(12):1529-1537. PubMed ID: 29116411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The NINDS Parkinson's disease biomarkers program.
    Rosenthal LS; Drake D; Alcalay RN; Babcock D; Bowman FD; Chen-Plotkin A; Dawson TM; Dewey RB; German DC; Huang X; Landin B; McAuliffe M; Petyuk VA; Scherzer CR; Hillaire-Clarke CS; Sieber BA; Sutherland M; Tarn C; West A; Vaillancourt D; Zhang J; Gwinn K;
    Mov Disord; 2016 Jun; 31(6):915-23. PubMed ID: 26442452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exercise- and strategy-based physiotherapy-delivered intervention for preventing repeat falls in people with Parkinson's: the PDSAFE RCT.
    Ashburn A; Pickering R; McIntosh E; Hulbert S; Rochester L; Roberts HC; Nieuwboer A; Kunkel D; Goodwin VA; Lamb SE; Ballinger C; Seymour KC
    Health Technol Assess; 2019 Jul; 23(36):1-150. PubMed ID: 31339100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measuring hot flashes: summary of a National Institutes of Health workshop.
    Miller HG; Li RM
    Mayo Clin Proc; 2004 Jun; 79(6):777-81. PubMed ID: 15182093
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Challenges of modifying disease progression in prediagnostic Parkinson's disease.
    Salat D; Noyce AJ; Schrag A; Tolosa E
    Lancet Neurol; 2016 May; 15(6):637-48. PubMed ID: 26993435
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson's disease patients for the identification and validation of biomarkers for Parkinson's disease subtypes, progression and pathophysiology.
    Boertien JM; van der Zee S; Chrysou A; Gerritsen MJJ; Jansonius NM; Spikman JM; van Laar T;
    BMC Neurol; 2020 Jun; 20(1):245. PubMed ID: 32534583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What causes cell death in Parkinson's disease?
    Gupta A; Dawson VL; Dawson TM
    Ann Neurol; 2008 Dec; 64 Suppl 2(0 2):S3-15. PubMed ID: 19127586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sepsis Care Pathway 2019.
    Labib A
    Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
    [No Abstract]   [Full Text] [Related]  

  • 50. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic.
    Sardi SP; Cedarbaum JM; Brundin P
    Mov Disord; 2018 May; 33(5):684-696. PubMed ID: 29704272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?
    Le W; Dong J; Li S; Korczyn AD
    Neurosci Bull; 2017 Oct; 33(5):535-542. PubMed ID: 28866850
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomarkers for the diagnosis and management of Parkinson's disease.
    Waragai M; Sekiyama K; Fujita M; Tokuda T; Hashimoto M
    Expert Opin Med Diagn; 2013 Jan; 7(1):71-83. PubMed ID: 23530844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cerebrospinal fluid biomarkers in Parkinson disease.
    Parnetti L; Castrioto A; Chiasserini D; Persichetti E; Tambasco N; El-Agnaf O; Calabresi P
    Nat Rev Neurol; 2013 Mar; 9(3):131-40. PubMed ID: 23419373
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).
    Williams-Gray CH; Wijeyekoon R; Yarnall AJ; Lawson RA; Breen DP; Evans JR; Cummins GA; Duncan GW; Khoo TK; Burn DJ; Barker RA;
    Mov Disord; 2016 Jul; 31(7):995-1003. PubMed ID: 26999434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease.
    Zeighami Y; Fereshtehnejad SM; Dadar M; Collins DL; Postuma RB; Dagher A
    Neuroimage Clin; 2019; 24():101986. PubMed ID: 31514113
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug Repurposing in Parkinson's Disease.
    Athauda D; Foltynie T
    CNS Drugs; 2018 Aug; 32(8):747-761. PubMed ID: 30066310
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical measures of progression in Parkinson's disease.
    Poewe W
    Mov Disord; 2009; 24 Suppl 2():S671-6. PubMed ID: 19877235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging.
    Yang J; Burciu RG; Vaillancourt DE
    Curr Neurol Neurosci Rep; 2018 Oct; 18(12):83. PubMed ID: 30280267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.